Clinical trials: Pulmonary Hypertension
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Hypertension, Pulmonary
Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
The primary objective in this study is to collect post-marketing information on Riociguat safety.Thus, the information on adverse events (AEs) and adverse drug reactions (ADRs) that occur within the first 12 months and in the…
- Trial name
- JPMS-PAH (NCT02428985)
- Testing
- Riociguat (ADEMPAS, BAY63-2521)
- Where
- Japan
- Volunteers
- 882 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
- Trial name
- NCT02304198
- Testing
- Udenafil
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Dong-A ST Co., Ltd.
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
High Altitude Pulmonary Hypertension
Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis.
- Trial name
- HAPE (NCT06852924)
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Novlead Inc.
Hypertension, Pulmonary
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
The objective of this post-marketing surveillance study is to evaluate the incidence of adverse events in Japanese subjects with pulmonary arterial hypertension treated with ambrisentan basd on prescribing information under the…
- Trial name
- NCT01406327
- Testing
- Ambrisentan
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Pulmonary Hypertension
Evaluation of Lung Doppler Signals in Pulmonary Hypertension
The purpose of this study is to evaluate the lung Doppler signals in patients with pulmonary hypertension that undergo (prospective arm) or underwent (retrospective arm) right heart catheterization (RHC) in order to assess…
- Trial name
- NCT01839786
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Echosense Ltd.
Pulmonary Arterial Hypertension
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the…
- Trial name
- INHALE-15 (NCT00723554)
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 36 sites in United States
- Volunteers
- 63 people
- Sponsor
- Actelion
Systemic Sclerosis, Pulmonary Arterial Hypertension
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- DETECT (NCT00706082)
- Where
- 83 sites in United States, Austria and 18 more
- Volunteers
- 490 people
- Sponsor
- Actelion
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- PADN-HF-PH (NCT05824923)
- Testing
- Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Pulmonary Arterial Hypertension
Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses of MK-8892 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT01934647
- Testing
- MK-8892
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil. To assess the effect of sildenafil on the PK of BIA 5-1058.
- Trial name
- NCT04994860
- Testing
- BIA 5-1058, Sildenafil
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label…
- Trial name
- NCT02279160
- Testing
- APD811
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 61 people
- Sponsor
- United Therapeutics
Pulmnary Hypertension
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
This prospective, observational study will evaluate whether synchronized heart sound (phonocardiogram, PCG) and three-lead electrocardiogram (ECG) recordings (entered as separate interventions in PRS, though collected together in…
- Trial name
- EKO-PH (NCT07136623)
- Testing
- Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording
- Where
- 2 sites in United States
- Volunteers
- 1,513 people, healthy volunteers welcome
- Sponsor
- Eko Devices, Inc.